The European Medicines Agency has announced a much-anticipated recommendation for two COVID-19 medicines: Ronapreve (casirivimab/imdevimab) from Swiss pharma giant Roche (ROG: SIX), and Regkirona (regdanvimab) from Celltrion Healthcare Hungary, a part of South Korea’s Celltrion Healthcare (Kosdaq: 068270), for COVID-19.
The EMA’s human medicines committee (CHMP) recommended authorising Ronapreve for treating COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of their disease becoming severe.
With regard to Regkirona, the Committee recommended authorizing the medicine for treating adults with COVID-19 who do not require supplemental oxygen and who are also at increased risk of their disease becoming severe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze